Prostate cancer |
NCT01817738 |
Terminated (I/II) |
RNActivetumour-associated antigen mRNA |
CureVac AG |
NCT00831467 |
Completed (I/II) |
NCT02140138 |
Terminated (II) |
NCT01446731 |
Completed (II) |
Dendritic cell loaded with tumour-associated antigen mRNA |
Herlev Hospital |
NCT01197625 |
Recruiting (I/II) |
Oslo University Hospital |
NCT01278914 |
Completed (I/II) |
NCT00906243 |
Terminated (I/II) |
RNActivetumour-associated antigen mRNA |
University of Florida |
Glioblastoma |
NCT02649582 |
Recruiting (I/II) |
Dendritic cell electroporated with tumour-associated antigen mRNA |
Antwerp University Hospital |
NCT02465268 |
Recruiting (II) |
Dendritic cell loaded with cytomegalovirus antigen mRNA with granulocyte–macrophage colony-stimulating factor protein |
University of Florida |
NCT02366728 |
Active (II) |
Dendritic cell loaded with cytomegalovirus antigen mRNA |
Duke University |
NCT00626483 |
Completed (I) |
NCT02529072 |
Completed (I) |
NCT00639639 |
Active (I) |
NCT00890032 |
Completed (I) |
Dendritic cell loaded with autologous tumour mRNA |
NCT02709616 |
Active (I) |
Dendritic cell loaded with tumour-associated antigen mRNA |
Guangdong 999 Brain Hospital |
NCT02808364 |
NCT00846456 |
Completed(I/II) |
Dendritic cell loaded with autologous tumour or tumour-associated antigen mRNA |
Oslo University Hospital |
Pancreatic cancer |
NCT00664482 |
Completed (Not applicable) |
Dendritic cell electroporated with autologous tumour mRNA with or without CD40L mRNA |
Argos Therapeutics |
Melanoma |
NCT02035956 |
Completed (I) |
Naked tumour-associated antigen or neo−Ag mRNA |
BioNTech RNA Pharmaceuticals GmbH |
NCT01684241 |
NCT02410733 |
Active (I) |
Liposome-complexed tumour-associated antigen mRNA |
NCT01216436 |
Terminated |
Dendritic cell, matured, loaded with tumour-associated antigen mRNA |
Duke University |
NCT01456104 |
Active (I) |
Dendritic cell (Langerhans) electroporated with tumour-associated antigen mRNA |
Memorial Sloan Kettering Cancer Center |
NCT01278940 |
Completed (I/II) |
Dendritic cell loaded with autologous tumour or tumour-associated antigen mRNA |
Oslo University Hospital |
NCT00961844 |
Terminated (I/II) |
NCT02285413 |
Completed (II) |
Dendritic cellelectroporated with tumour or tumour-associated antigen mRNA |
Radboud University |
NCT01530698 |
Completed (I/II) |
NCT00940004 |
Completed (I/II) |
NCT00243529 |
Completed (I/II) |
NCT00929019 |
Terminated (I/II) |
Melanoma |
NCT00204516 |
Completed (I/II) |
Autologous tumour mRNA with granulocyte–macrophage colony-stimulating factor protein |
University Hospital Tübingen |
NCT00204607 |
Completed (I/II) |
Protamine-complexed tumour-associated antigen mRNA with macrophage colony-stimulating factor protein |
NCT01983748 |
Recruiting (III) |
Matured Dendritic cell, loaded with autologous tumour RNA |
University Hospital Erlangen |
NCT01676779 |
Completed (II) |
Dendritic cellelectroporated with tumour-associated antigen and TriMix mRNA |
UniversitairZiekenhuisBrussel |
NCT01066390 |
Completed (I) |
NCT01302496 |
Completed (II) |
Colorectal cancer |
NCT00228189 |
Completed (I/II) |
Dendritic cellelectroporated with tumour-associated antigen mRNA |
Radboud University |
Ovarian cancer |
NCT01334047 |
Terminated (I/II) |
Dendritic cell loaded with autologous tumour or tumour-associated antigen mRNA |
Oslo University Hospital |
NCT01456065 |
Unknown |
Matured Dendritic cell, loaded with autologous tumour RNA |
Life Research Technologies GmbH |
Breast cancer z |
NCT02316457 |
Active (I) |
Liposome-formulated tumour-associated antigen and neo−antigen mRNA |
BioNTech RNA Pharmaceuticals GmbH |
NCT00978913 |
Completed (I) |
Dendritic cellloaded with tumour-associated antigen mRNA |
Herlev Hospital |
Acute Myeloid Leukemia |
NCT00514189 |
Terminated (I) |
Dendritic cell loaded with Acute Myeloid Leukemia lysate and mRNA |
MD Anderson Cancer Center |
NCT01734304 |
Completed (I/II) |
Dendritic cell loaded with tumour-associated antigen and cytomegalovirus antigenmRNA |
Ludwig-Maximilian-University of Munich |
NCT00510133 |
Completed (II) |
Dendritic cell loaded with tumour-associated antigen mRNA |
AsteriasBiotherapeutics |
NCT00965224 |
Unknown (II) |
Dendritic cellelectroporated with tumour-associated antigen mRNA |
Antwerp University Hospital |
NCT01686334 |
Recruiting (II) |
NCT00834002 |
Completed (I) |
NCT03083054 |
Active (I/II) |
Dendritic cell loaded with tumour-associated antigen mRNA |
University of Campinas, Brazil |
Brain metastases |
NCT02808416 |
Active (I) |
Dendritic cell loaded with tumour-associated antigen mRNA |
Guangdong 999 Brain Hospital |
Non-small-cell lung cancer |
NCT01915524 |
Terminated (I) |
RNActivetumour-associated antigen mRNA |
CureVac AG |
NCT00923312 |
Completed (I/II) |
Renal cell carcinoma |
NCT00087984 |
Completed (I/II) |
Dendritic cell electroporated with autologous tumour mRNA with or without CD40L mRNA |
Argos Therapeutics |
NCT01482949 |
Terminated (II) |
NCT01582672 |
Terminated (III) |
NCT00678119 |
Completed (II) |
NCT00272649 |
Completed (I/II) |
Mesothelioma |
NCT02649829 |
Recruiting (I/II) |
Dendritic cell electroporated with tumour-associated antigen mRNA |
Antwerp University Hospital |